TY  - GEN
AU  - Aranda,E
AU  - García-Alfonso,P
AU  - Benavides,M
AU  - Sánchez Ruiz,A
AU  - Guillén-Ponce,C
AU  - Safont,M J
AU  - Alcaide,J
AU  - Gómez,A
AU  - López,R
AU  - Manzano,J L
AU  - Méndez Ureña,M
AU  - Sastre,J
AU  - Rivera,F
AU  - Grávalos,C
AU  - García,T
AU  - Martín-Valadés,J I
AU  - Falcó,E
AU  - Navalón,M
AU  - González Flores,E
AU  - Ma García Tapiador,A
AU  - Ma López Muñoz,A
AU  - Barrajón,E
AU  - Reboredo,M
AU  - García Teijido,P
AU  - Viudez,A
AU  - Cárdenas,N
AU  - Díaz-Rubio,E
TI  - First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
SN  - 1879-0852
PY  - 2019///0415
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Cetuximab
KW  - administration & dosage
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Exanthema
KW  - chemically induced
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Leucovorin
KW  - Maintenance Chemotherapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neutropenia
KW  - Organoplatinum Compounds
KW  - Proto-Oncogene Proteins p21(ras)
KW  - genetics
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ejca.2018.06.024
ER  -